The humoral response to COVID-19 vaccinations can predict the booster effect on health care workers-toward personalized vaccinations?

SARS-COV-2 antibodies booster humoral response vaccine effectiveness

Journal

Journal of public health (Oxford, England)
ISSN: 1741-3850
Titre abrégé: J Public Health (Oxf)
Pays: England
ID NLM: 101188638

Informations de publication

Date de publication:
23 Oct 2023
Historique:
received: 14 02 2023
revised: 21 09 2023
accepted: 24 09 2023
medline: 24 10 2023
pubmed: 24 10 2023
entrez: 24 10 2023
Statut: aheadofprint

Résumé

Waning immunity after the coronavirus disease 2019 (COVID-19) vaccinations creates the constant need of boosters. Predicting individual responses to booster vaccines can help in its timely administration. We hypothesized that the humoral response to the first two doses of the BNT162b2 vaccine can predict the response to the booster vaccine. A prospective cohort of hospital health care workers (HCW) that received three doses of the BNT162b2 vaccine. Participants completed serological tests at 1 and 6 months after the second vaccine dose and 1 month after the third. We analyzed predictive factors of antibody levels after the booster using multivariate regression analyses. From 289 eligible HCW, 89 (31%) completed the follow-up. Mean age was 48 (±10) and 46 (52%) had daily interaction with patients. The mean (±standard deviation) antibody level 1 month after the second vaccine was 223 (±59) AU/ml, and 31 (35%) had a rapid antibody decline (>50%) in 6 months. Low antibody levels 1 month after the second vaccine and a rapid antibody decline were independent predictors of low antibody levels after the booster vaccine. The characteristics of the humoral response to COVID-19 vaccinations show promise in predicting the humoral response to the booster vaccines.

Sections du résumé

BACKGROUND BACKGROUND
Waning immunity after the coronavirus disease 2019 (COVID-19) vaccinations creates the constant need of boosters. Predicting individual responses to booster vaccines can help in its timely administration. We hypothesized that the humoral response to the first two doses of the BNT162b2 vaccine can predict the response to the booster vaccine.
METHODS METHODS
A prospective cohort of hospital health care workers (HCW) that received three doses of the BNT162b2 vaccine. Participants completed serological tests at 1 and 6 months after the second vaccine dose and 1 month after the third. We analyzed predictive factors of antibody levels after the booster using multivariate regression analyses.
RESULTS RESULTS
From 289 eligible HCW, 89 (31%) completed the follow-up. Mean age was 48 (±10) and 46 (52%) had daily interaction with patients. The mean (±standard deviation) antibody level 1 month after the second vaccine was 223 (±59) AU/ml, and 31 (35%) had a rapid antibody decline (>50%) in 6 months. Low antibody levels 1 month after the second vaccine and a rapid antibody decline were independent predictors of low antibody levels after the booster vaccine.
CONCLUSIONS CONCLUSIONS
The characteristics of the humoral response to COVID-19 vaccinations show promise in predicting the humoral response to the booster vaccines.

Identifiants

pubmed: 37872715
pii: 7328860
doi: 10.1093/pubmed/fdad198
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Ophir Freund (O)

The Institute of Pulmonary Medicine, Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Alma Harish (A)

Division of Pulmonary Medicine, Barzilai Medical Center, Ashkelon, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Anna Breslavsky (A)

Division of Pulmonary Medicine, Barzilai Medical Center, Ashkelon, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Ori Wand (O)

Division of Pulmonary Medicine, Barzilai Medical Center, Ashkelon, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Nadav Zacks (N)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Natalya Bilenko (N)

Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Medical Office of Southern District, Ministry of Health, Ashkelon, Israel.

Amir Bar-Shai (A)

The Institute of Pulmonary Medicine, Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Division of Pulmonary Medicine, Barzilai Medical Center, Ashkelon, Israel.

Classifications MeSH